FIA
HRTX icon

FNY Investment Advisers’s Heron Therapeutics HRTX Stock Holding History

FNY Investment Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,700
Closed -$338K – 820
2018
Q3 		$338K Buy
10,700
+10,200
+2,040% +$380K 0.08% 144
2018
Q2 		$19K Buy
+500
New +$15.9K 0.01% 366

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FNY Investment Advisers's HRTX Position: Q4 2018 in Review

FNY Investment Advisers sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 10,700 shares — an estimated $338K sold.

FNY Investment Advisers first reported a position in HRTX in Q2 2018 and held it in 2 quarters. The position peaked at $338K in Q3 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

  • FNY Investment Advisers reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 10,700 Heron Therapeutics shares in Q4 2018, an estimated $338K.
  • FNY Investment Advisers first reported a position in Heron Therapeutics in Q2 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Heron Therapeutics position peaked at $338K in Q3 2018.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.